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 Clinical phenotypes and endophenotypes of atopic dermatitis: Where are 
we, and where should we go? 
Thomas Bieber, MD, PhD, MDRA,a,b Angelo M. D’Erme, MD,c,d Cezmi A. Akdis, MD,b,e Claudia Traidl-Hoffmann, MD,b,f 
Roger Lauener, MD,b,g Georg Schappi, PhD,b and Peter Schmid-Grendelmeier, MDb,h Bonn and Munich, Germany; 
Zurich, Davos, and St Gallen, Switzerland; and Livomo and Pisa, Italy 
Atopic dermatitis (AD) is a paradigmatic chronic inflammatory skin 
disease characterized by a complex pathophysiology and a wide 
spectrum of the clinical phenotype. Despite this high degree 
ofheterogeneity,ADisstillconsideredasinglediseaseandusually 
treated according to the ‘‘one-size-fits-all’’ approach. Thus more 
tailoredprevention and therapeutic strategies arestill lacking.As for 
other disciplines, such as oncology or rheumatology, we have to 
approach AD in a more differentiated way (ie, to dissect and 
stratify the complex clinical phenotype into more homogeneous 
subgroups based on the endophenotype [panel of biomarkers]) with 
the aim to refine the management of this condition. Because we are 
now entering the era of personalized medicine, a systems biology 
approachmerging the numerous clinical phenotypeswith robust (ie, 
relevant and validated) biomarkers will be needed to best exploit 
their potential significance for the future molecular taxonomy of 
AD. This approach will not only allow an optimized prevention and 
treatment with the available drugs but also hopefully help assign 
newly developed medicinal products to those patients who will 
have the best benefit/risk ratio. (J Allergy 
Clin Immunol 2017;139:S58-64.) 
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Atopic dermatitis (AD) is the most common chronic 
inflammatory skin disorder.1 The disease represents a substantial 
socioeconomic burden,2,3 partly because of the lack of an 
efficient therapeutic armamentarium able to control the disease 
in the long term.4 Most of the physicians who take care of 
patients with AD are well aware of the high degree of 
heterogeneity of the clinical phenotype and the debated role of 
IgE-mediated sensitization or food allergy.5,6 The latter is only 
one among many provocative factors claimed to be instrumental 
in inducing flares and/or supporting the chronic inflammation 
and itching sensation. 
 Our current understanding of the disease has dramatically 
evolvedoverthelastyears, mainlybecause ofsubstantialprogress in 
epidemiology and genetics, further supporting the concept of the 
atopic march7 but also unraveling new aspects with regard to the 
natural history8,9 and persistence of AD over a lifetime.10,11 Many 
pioneering discoveries have unraveled the critical genetic 
predisposition underlying epidermal barrier dysfunction,12,13 as 
well as the intimate immunologic mechanisms working as forces 
driving chronic inflammation,14 and triggering the emergence of 
IgE-mediated sensitization15 and contact sensitization.16 
Despite the obvious complexity of the clinical phenotype, we 
are still treating AD according to the ‘‘one-size-fits-all’’ 
approach and are neglecting a more differentiated method based 
on stratification of AD.17,18 Change will come through a better 
understanding of the different genetic and immunologic 
mechanisms underlying the wide spectrum of disease 
phenotypes. The roadmap toward a precision medicine approach 
in AD management will be mainly dictated by the discovery and 
validation of reliable biomarkers that will enable the physician 
to provide more tailored management, starting from prevention 
strategiesand movinguptotreatmentofpatientswithmoresevere 
disease with targeted therapies.19-21 A clear definition of 
different clinical phenotypes on the one hand and potential 
biomarkers providing the adequate respective endophenotypes 
are key elements for successful development of newtherapeutic 
options22 and implementation of precision medicine in patients 
with AD. 
CLINICAL PHENOTYPES Stratification based on the age-
related clinical picture 
The clinical picture of AD varies substantially depending on 
the age of the patient.1 Typically, at least 4 different kinds of 
clinical features have been defined23 as follows: infantile, 
childhood, adolescent/adult, and elderly. Although acute lesions 
predominate more in the infantile spectrum, chronic lesions, 
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including strong lichenification, typically appear later and are 
sometimes combined into more nodular lesions corresponding 
to the prurigo phenotype. Except for the very initial stage of the 
disease during the first weeks of life, pruritus remains a typical 
hallmark in all stages. 
Infantile AD (between 3 months and 2 years of age). The 
first lesions emerge around the second month of life and 
typically affect the cheeks with edematous papules and 
papulovesicles. They can form large plaques with oozing and 
crusting. The scalp also shows extensive scaling of the so-
called cradle cap. Furthermore, the scalp, neck, and extensor 
parts of the extremities, as well as the trunk, can be involved, 
sparing the diaper area. Most importantly, the very initial stage 
of the disease might be very difficult to diagnose, whereas the 
more typical eczematous lesions on respective localizations can 
appear a few weeks later. 
Childhood AD (age 2-12 years). At this stage, acute lesions 
still appear, but chronic lesions with some lichenification tend 
to be at the forefront. The predilection sites are the popliteal 
and antecubital fossa (flexural eczema), as well as the 
periorificial areas on the head. Quite often, the hands and wrists 
show rather nummular plaques with oozing and crusting 
corresponding to a nummular type of the disease. Dry skin 
(xerosis) becomes more dominant. 
AD in adolescents and adults (age >12 up to 
60 years). In this period of life, the lesions are more fixed to 
classical areas, such as the head, neck, and flexural areas. 
Moreover, in adults the disease can also affect the hands 
(chronic hand dermatitis). In female subjects the disease also 
often involves the periorbital areas. In patients with a long-
standing natural history of the disease, AD is more likely to 
have an extensive and sometimes erythrodermic aspect. 
AD in the elderly (age >60 years). This seems to be a rather 
underestimated clinical phenotype of AD (see ‘‘Natural history 
of AD’’). This form is mostly characterized by extensive 
eczematous lesions up to erythrodermic aspects with a strong 
pruritic component. Sometimes the lesions spare the flexural 
areas. This particular phenotype certainly needs a more 
profound analysis to define clear-cut clinical criteria for its 
definitive diagnosis. In the elderly a number of differential 
diagnoses should be excluded that might mimic AD, such as 
allergic contact dermatitis and cutaneous T-cell lymphoma. 
Stratification based on disease severity 
As already mentioned, AD can cover a wide spectrum in 
terms of severity, ranging from very mild to very severe 
phenotypes. In addition to the classical diagnostic criteria, the 
definition of severity as mild, moderate, or severe is best 
obtained by using validated scoring systems, such as the 
SCORAD or Eczema Area and Severity Index scores. For the 
purposes of pivotal (phase 3) clinical trials, some regulatory 
agencies, such as the US Food and Drug Administration, 
request the so-called Investigator Global Assessment as a 
primary end point with a 5- or 6-point scale that has never been 
properly validated. An attempt to align these different scoring 
systems in a single chart is presented in Fig 1 
SCORAD 
 
EASI 
FIG 1. Clinical phenotype: stratification according to severity, as exemplified by 
SCORAD and Eczema Area and Severity Index (EASI) scores (based on Leshem et al24). 
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(based on Leshem et al24). Such an alignment might be useful to 
compare the efficacy of primary or secondary end points from 
different studies, such as in a meta-analysis. There is still debate 
as to which scoring system is the easiest to use for physicians in 
daily practice, who face therapeutic decisions involving new 
active substances, such as biologics. 
The so-called atopic stigmata, which represent clinical 
findings apart from eczematous lesions, might also represent 
particular variants of the mild forms of AD and are more helpful 
for a classification in relationship to the atopic diathesis.25 
Stratification based on age of onset 
Another way to stratify patients affected by AD is to classify 
them according to the natural history of the disease. This has 
many implications for our understanding of epidemiologic 
aspects and for our understanding of the dynamics of the disease, 
which can be imprinted by different kinds of immunologic 
mechanisms. Finally, being able to identify those patients with 
the highest risk of an ongoing chronic inflammation and a long-
term disease history would provide significant progress in the 
targeted approach to prevention through early intervention. 
Although in the past AD was traditionally considered a disease 
primarily occurring in childhood and potentially resolving in a 
completeand definitive remission in morethan 50%of patients up 
to age 10 years, more recent epidemiologic evidence supports 
the concept that, once acquired, AD can persist for the rest of a 
patient’s life. 
Follow-up studies of patients and retrospective analyses have 
identified at least 6 different types of onset of AD. In agreement 
with the notion that such phenotypes might represent distinct 
subentities is the observation that they are influenced by 
different environmental exposures effective at different ages. In 
support of this assumption, prenatal maternal contact with 
animals goes along with protection against AD manifesting 
during the first year of life,26 whereas feeding habits during the 
first year of life are associated with AD with an onset after the 
first year of life.27,28 These types of onset are summarized in Fig 
29 and described below. 
Very early onset (between 3 months and 2 years). 
Depending on epidemiologic studies, this type of onset 
represents 60% to 80% of all forms of AD onset. A substantial 
portion of patients can go into complete remission before age 2 
years. Another portion, which is estimated roughly at 40%, 
continues to have the disease over a longer period of time and 
could represent the population with the highest risk for the atopic 
march. 
 
FIG 2. Clinical phenotype: stratification according to age of onset. Curves indicate age 
of onset and possible natural histories (based on Garmhausen et al9). 
Early onset (between 2 and 6 years). Early onset represents 
another subgroup of the phenotype in terms of age of onset, and 
these patients also bear a high risk of having chronic disease. 
Childhood onset (between 6 and 14 years) 
Childhood onset represents a rather small group of patients 
(approximately 10%) for whom the fate of the disease has not 
clearly been explored. 
Adolescent type of onset (between 14 and 18 years) 
Adolescent onset represents probably the smallest group 
(<10%), for which there are only limited epidemiologic data 
about the fate of the disease. 
Adult onset (between 20 and 60 years). Adult onset is an 
interesting group, representing about 20% of the overall 
population, and is characterized mainly by female patients with a 
rather mild clinical phenotype and a very limited spectrum of 
sensitization, usually accompanied by a normal total IgE level. 
Very late onset (>60 years). Thegroup withverylate onset has 
been identified more recently29 and seems to represent a 
subgroup of increasing significance. Within this group of old 
patients, at least 2 further subgroups can be identified: those who 
had AD in the past but had a longer period of remission and 
those who start the disease very late in life.30 Very often, these 
patients present with a rather severe form of the disease and high 
total IgE levels. Clearly, as is the case for the very early onset 
group between 3 and 6 months, clear criteria for the diagnosis of 
this particular group in the older generation are missing. 
Stratification based on ethnic origin of the patients 
For a long time, it has been assumed that the clinical picture of 
AD is identical, irrespective of the world region and ethnic 
origin of the patients. Recently, a pioneering work addressing the 
transcriptomic profile of white patients and patients from Asian 
populations suggested that there might be substantial differences 
in the profile of the cytokines driving chronic inflammation in 
the latter populations.31 In addition to the expected TH2 profile, 
patients from Japan and Korea also have strong TH17 expression 
in skin lesions. This observation correlates with histologic 
changes showing more pronounced epidermal hyperplasia and, 
clinically, an overall more pronounced lichenification of the 
lesions. On the other hand, the clinical picture of AD lesions in 
African Americans has also been reported to be different from 
the classical picture described in the white population.32 Also, 
pathophysiologic differences have been observed because, for 
example, filaggrin deficiency, which is commonly found in 
white patients, was not observed in South African patients with 
AD.33 Therefore it is likely that further studies will show 
variations of the clinical phenotype depending on the ethnic 
origin of the patients and that this phenomenon is mirroring 
significant differences in the pathomechanisms underlying 
chronic inflammation. This is further supported by the 
observation of different hotspots in the filaggrin mutations 
reported between white and Asian populations.34 It cannot be 
20 14  J 0 >60
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 excluded that some of the diagnostic criteria mainly generated 
and validated in the white population will have to be revised and 
adapted according to other ethnic variants of AD. Further 
evidence for the need of a more adapted diagnostic approach has 
been provided in a recent analysis in Chinese children.35,36 
Ultimately, this might have a profound effect on therapeutic 
strategies involving new active substances targeting cytokines 
and other structures assumed to be key players in the respective 
subgroup of patients worldwide. 
ENDOPHENOTYPES AND BIOMARKERS: 
MANDATORY TOOLS FOR STRATIFICATION OF AD 
According to the World Health Organization, biomarkers are 
considered as ‘‘any substance, structure or process that can be 
measured in the body or its products and influences or predicts 
the incidence of outcome of disease or disease.’’ Moreover, 
according to the definition of the National Institutes of Health 
Biomarker Definition Working Group,37 ‘‘a biomarker is a 
characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes 
or pharmacologic response to a therapeutic intervention.’’ 
Hence any kind of measurable characteristic that bears a 
diagnostic, prognostic, or predictive value can be considered a 
biomarker. 
Endophenotypesaredefinedasmeasurable componentsunseen 
by the unaided eye along the pathway between disease and 
distal genotype.38 Thus the endophenotype is made of a 
collection of biomarkers between the clinical phenotype and 
genotype. Ultimately, this individual biosignature might also 
include data obtained from their environmental life (ie, the 
exposome). In fact, in addition to the clinical phenotype, 
biomarkers and endophenotypes are now considered 
fundamental tools that will enable us to stratify highly complex 
diseases into subgroups for which more tailored prevention and 
therapeutic strategies have to be developed. More than 
individual biomarkers, it is expected that a combination or a 
panel of different biomarkers will be used for the stratification 
of complex phenotypes, as we already learned from the field of 
oncology, in which therapeutic decisions are taken more and 
more often based on this kind of approach. 
In contrast to the clinical phenotypes, the biomarker 
discovery and definition of endophenotypes is only at an early 
stage and represents a substantial unmet need. Hence there is no 
clear endophenotype defined for AD. In the context of precision 
medicine, at least 7 different types of biomarkers can be 
considered for AD (Table I).39 It should be emphasized that 
none of the mentioned candidate biomarkers have reached the 
step of validation thus far. 
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Screening biomarkers allowing identification of patients 
with high risk of AD before first clinical signs of the disease 
With regard to the natural history of AD in infancy and 
childhood, it would make sense to use screening biomarkers to 
identify those newborns at high risk of AD. Because it has been 
shown that early intervention directly after birth in such a 
subpopulation selected on the basis of family history might at 
least delay the appearance of the disease,40,41 the question arises 
of which biomarker or biomarker combination would allow us 
to select those newborns who will potentially have the best 
benefit from this kind of early intervention. Recently, it has 
been reported that measurement of transepidermal water loss 
could be a simple and noninvasive method to select these 
subjects.42 
Screening for mutations and variants in the genes encoding 
epidermal structural proteins, such as filaggrin 1 and 2,43 would 
also represent a potential way to identify subjects with a high 
risk of having AD44 and undergoing the atopic march.45 
Although genotyping still remains a rather cumbersome and 
expensive approach, it is expected that this technology will be 
applicable for screening approaches in the near future. 
Similarly, exploring the risk for AD based on analysis of 
mutations and variants of other genes encoding for structural 
proteins, such as serine protease inhibitor Kazal-type 5/lympho-
epithelial Kazal-type-related inhibitor (SPINK5/LEKTI)46 or 
thymic stromal lymphopoietin,47 could be useful to detect 
populations at high risk of disease. 
Diagnostic biomarkers helping in early diagnosis of the 
disease and in the case of differential diagnostic problems 
Although the diagnosis of AD is performed mainly based on 
clinical signs, physicians are struggling at the 2 ends of the age 
spectrum: the very early phase of life before the age of 3 to 4 
months and in the elderly, as mentioned above. Unfortunately, 
none of the currently available biomarker candidates48,49 have 
been tested in these 2 particular situations, and therefore there 
is clearly an unmet need in the field of biomarker discovery to 
answer this crucial question. 
J ALLERGY CLIN IMMUNOL 
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TABLE I. Subtypes of candidate biomarkers in AD 
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Biomarker Screening Diagnostic Severity  Sensitization Predictive therapeutic response  Prognostic fate of AD/comorbidities 
Total/specific IgE 
1 
 
 
1 
111 
1 
 111  Potential for prevention  ? 
TARC/CCL17  
  
 
 
MDC/CCL22   
CTACK/CCL27  
FLG1/2  11     Potential for prevention  ? 
SPINK5/LEKTI 1 
 
1 
1 
1 
1 
1 
 
? 
 
? 
 
Potential for prevention 
 ? 
TSLP  1  Risk for viral complication 
IL-31 
 
11 
  
IL-33  Risk for viral complication 
IL-22  
 
Risk for EH 
FcεRI/FcgRII 
IDO 
LL-37   
IL-18  
 
? 
IL-16 
Soluble IL-2 receptor 
PARC/CCL18 
TEWL 
Periostin   1       
BDNF  1      
IgE against Malassezia 
species 
  1   1 
 
BNDF, Brain-derived neurotrophic factor; CTACK, cutaneous T-cell-attracting chemokine; EH, eczema herpeticum; FLG, filaggrin; IDO, indolamine-2,3-dioxygenase; MDC, 
macrophage-derived chemokine; PARC, pulmonary and activation-regulated chemokine; SPINK5/LEKTI, serine protease inhibitor Kazal-type 5/lympho-epithelial Kazal-
typerelated inhibitor; TARC, thymus and activation-regulated chemokine; TEWL, transepidermal water loss; TSLP, Thymic stromal lymphopoietin. 
 
 Severity biomarkers that can be used as support in clinical 
trials for evaluation of therapeutic success and/or as 
surrogate markers for therapeutic response in the context of 
long-term disease control 
Most of the potential biomarkers described thus far in the 
literature are more or less related to the issue of severity and 
their changes during the therapeutic regimen. Among these, 
thymus and activation-regulated chemokine (CCL17), 
macrophagederived chemokine (CCL22), cutaneous T-cell-
attracting chemokine (CCL27), IL-31, IL-33, IL-22, LL37, IL-
18, IL-16, pulmonary and activation-regulated chemokine 
(CCL18), periostin, and the soluble IL-2 receptor and brain-
derived neurotrophic factor are the most prominent candidates.50-
59 Also, sensitization to skin-colonizing yeast, such as Malassezia 
species or autoallergens, has been described as a possible marker 
of disease activity60 and also for autoimmunity (see below). 
However, because the clinical effect of a therapeutic strategy is 
best appreciated based on objective evaluation by the physician 
and patient, the value of this kind of biomarker in the context of 
clinical trials and in real-world dermatologic practice remains 
rather limited. 
Biomarkers assessing the individual sensitization profile 
Obviously, measuring total IgE levels and, more particularly, 
specific IgE levels is a useful way to appreciate the sensitization 
profile of a given patient not only as a screenshot but also in 
follow-up during the natural course of the disease. The 
dichotomic view of AD61 in intrinsic (also called atopiform) 
versus extrinsic forms remains questionable62,63 because it is 
mainly based on measurement of total IgE levels and a limited 
panel of specific IgE levels in a given subject.64 Thus, rather than 
2 completely different forms of AD, the so-called intrinsic and 
extrinsic forms of AD most probably represent 2 opposite parts 
of one spectrum of the disease. Indeed, variations in dominance 
in the cytokine profile might account for this phenomenon. 
Clinical practice has shown that there is a significant proportion 
of patients with seemingly normal total IgE levels (ie, <100 
kU/mL) but who also have significant specific IgE levels against 
common allergens, such as pollen, house dust mite, or some 
particular food allergens. Therefore, more than the total IgE 
level, determination of the ratio of a given specific IgE level to 
the total IgE level might be a more useful biomarker to evaluate 
more objectively the sensitization profile and the potential 
usefulness of particular therapeutic interventions, such as 
allergen-specific immunotherapy. With increasing insight into 
sensitization on a molecular level, this might also contribute to 
the discovery of more subentities of AD.65 Moreover, it has been 
shown that there is a phenomenon of sensitization against self-
proteins in both children and adults,66 suggesting that at least 
some of the patients can display a particular form of AD, which 
can be considered an autoimmune form of the disease.67,68 
Therefore a refinement and standardization of the technology to 
measure specific IgE levels directed against autoallergens 
represents another interesting unmet need to address. Indeed, the 
presence of such specific IgE against self-protein would imply 
that avoidance of classical environmental allergens, including 
pollen, house dust mite, or food, might be useless in this 
subpopulation of patients. 
Predictive biomarkers for the therapeutic response and/or 
risk of side effects for a given active substance 
(pharmacogenomics) 
In contrast to the forthcoming biologics targeting particular 
cytokines instrumental in the pathomechanisms of the dis- 
ease,69,70 the thus far available therapeutic strategies are rather 
unspecific. Therefore the biomarker discovery in the field of 
therapeutic response remains completely neglected thus far. 
However, with regard to the knowledge accumulated recently in 
our understanding of the possibly diverging mechanisms driving 
chronic inflammation in children versus adults on the one hand 
and potentially also in different ethnic populations, the quest for 
biomarkers predicting the therapeutic response will be of 
significant importance. For example, the fact that AD in 
childhood shows a TH2, TH9, and TH17 polarization and in adults 
the T-cell response seems more TH22 dominant71,72 would 
suggest that current biologics targeting TH2 cytokines would be 
even more effective in children than in adults. Similarly, a 
potential TH17 dominance in the Asian population would allow 
the option to use anti–IL-17 biologics typically approved for 
psoriasis. 
Some biomarkers providing reliable information on the 
compliance of the patient would be helpful. Such 
biomarkerbased endophenotypes will have the potential to guide 
future therapeutic decisions based, for example, on analysis of 
the transcriptomic profile in the blood and skin. This new 
strategy has great potential in pharmacoeconomics in the era of 
personalized medicine when it comes to use of expensive 
targeted therapy options. 
Prognostic biomarkers that might predict risk for the atopic 
march, long-lasting remission phases, or comorbidities 
This type of biomarker is of utmost importance in the 
management of AD. Indeed, we learned from epidemiologic 
studies that the natural history of the disease (see above) and 
the thereby associated comorbidities, complications, or both are 
probably confined to some particular subgroups of patients. 
Prognostic biomarkers able to provide key information on the 
fate of the disease in childhood (ie, occurrence of remission 
before adolescence or continuous ongoing chronic 
inflammation) and, most importantly, the emergence of allergic 
asthma represent anotherunmetneed thatdeserves 
tobeaddressed. Also,the riskof severe viral complications,73 
such as eczema herpeticum, could be predicted.74 Moreover, 
because we learned that AD might represent a lifelong 
disease10,11 with potential phases of low activity levels and later 
reactivation, the availability of such prognostic biomarkers 
predicting this stage of life would be very helpful in terms of 
prevention of AD in older patients and the possible associated 
comorbidities.75 
UNMET NEEDS FOR STRATIFICATION OF AD IN THE ERA OF 
PRECISION MEDICINE 
A number of issues must be addressed to be able to provide a 
meaningful and practical stratification strategy for the clinical 
phenotype linked to more tailored preventative and therapeutic 
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approaches. This will help us reach the ultimate goal of 
precision medicine for AD and facilitate drug development. 
There is an increased number of biomarker candidates that have 
recently been identified in the context of our pathophysiologic 
understanding of this disease. However, as shown in Table I, 
there areanumberoffieldsinbiomarkerdiscoverythaturgentlyneed 
to be addressed to be able to enrich the panel of biomarkers 
with these different aims. By essence, biomarker discovery is a 
dynamic field very much related to emerging concepts in 
pathophysiology, as well as progress in the extended field of 
‘‘omics.’’ Ideally, detailed and high-quality phenotypical 
information from patients of large cohorts, as well as control 
subjects collected in registries and flanked biobanks, are key for 
biomarker discovery and validation and should be the focus of 
future research programs. This is the strategy followed by the 
Christine K€uhne–Center for Allergy Research and Education 
consortium (https://www.ck-care.ch/en/ck-care). 
Systems biology approaches will help to merge the 
information from clinical phenotypes with the increasing 
amount of data generated by using candidate biomarkers in this 
context to define reliable endophenotypes. Moreover, in 
addition to the validation issue, the fitness for use and 
qualification of biomarkers (Fig 3), particularly for those with a 
potential to be used as surrogate end points in clinical trials, 
will have to be addressed to implement use of these biomarker 
in daily practice. Merging the clinical phenotypic data from the 
registries from patients with AD with the newly discovered 
biomarkers from the biobank will potentially lead to a new 
molecular taxonomy of the disease, representing the 
groundwork for precision medicine. 
J ALLERGY CLIN IMMUNOL 
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Tools 
Stakeholders 
FIG 3. From 
biomarker discovery to fitness for use: steps of biomarker development until use in 
clinical trials or practice. None of the mentioned candidate biomarkers (Table I) have 
reached the step of validation. 
CONCLUSION 
AD is not a life-threatening disease but has a dramatic effect 
on quality of life of patients and their relatives and thereby 
represents a significant socioeconomic burden. It is still 
considered a single disease, and in addition to severity, disease 
management currently does not consider its highly 
heterogeneous clinical phenotype. It usually neglects the high 
rates of nonresponsiveness to this classical approach and the 
opportunities for prevention measures. This is especially valid 
for a substantial proportion of patients with AD of early onset, 
which is considered the first step in the development of other 
atopic disorders, such as allergic rhinitis, asthma, and food 
allergy (ie, the starting point of the atopic march). 
Thus, as in the field of oncology, where the discovery of 
biomarkers as companion diagnostics is becoming a key 
element in the development of new prevention and therapeutic 
strategies, the identification of new biomarkers in the field of 
dermatology and allergy bears a high potential for many 
purposes, such as diagnostic or prognostic algorithms. As we 
are now entering the era of stratified medicine, such biomarkers 
will play a fundamental role in improving management, with 
the potential to interfere in the ongoing pathophysiologic 
process through implementation of disease-modifying 
strategies. 
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